Venlafaxine hydrochloride sustained-release tablet preparation and preparation method thereof

Abstract

The invention discloses a venlafaxine hydrochloride sustained-release tablet preparation which comprises venlafaxine hydrochloride, framework material, diluent, lubricant, adhesive and coating material. The experiments demonstrate that the venlafaxine hydrochloride sustained-release tablet achieves better sustained-release effect, can reduce the dosing frequency and is convenient for the patients to use. The invention also provides a preparation method thereof.

Description

technical field

[0001] The invention relates to the field of pharmaceutical preparations, in particular to a novel antidepressant venlafaxine hydrochloride sustained-release tablet preparation and a preparation method thereof. Background technique

[0002] Venlafaxine is a novel phenethylamine derivative. Its mechanism of action is different from that of tricyclic antidepressants and newer selective serotonin reuptake inhibitors in that it exerts antidepressant effects through inhibition of norepinephrine and serotonin reuptake and weak inhibition of dopamine reuptake. Depressive effect, no inhibitory effect on monoamine oxidase, no affinity with cholinergic, histaminergic, adrenergic and other receptors, so there are no adverse reactions related to these receptors, such as sedation, dry mouth, constipation, urinary retention and blurred vision . Venlafaxine is a new type of antidepressant with rapid onset, good tolerance, and good short-term and long-term therapeutic effe...

Examples

Embodiment 1

[0060] Tablet formula: (made into 1000 tablets, each containing venlafaxine hydrochloride 75mg)

[0061]

[0062] Coating solution: aqueous dispersion of ethyl acrylate-methyl methacrylate copolymer

[0063] Preparation process: pass the above raw materials and supplements through 80-mesh sieve respectively, then mix evenly, directly compress into tablets, then coat with the above coating solution, and add talcum powder. Place the wrapped finished product at 40°C and keep it warm for 24 hours.

Embodiment 2

[0065] Tablet prescription: (made into 1000 tablets, each containing 75mg of venlafaxine hydrochloride)

[0066]

[0067] Coating solution: aqueous dispersion of ethyl acrylate-methyl methacrylate copolymer

[0068] Preparation process: pass the above raw materials and supplements through 80-mesh sieve respectively, then mix them evenly, make 16-mesh granules by dry method, compress into tablets, then coat with the above-mentioned coating solution, and add appropriate amount of talcum powder. Place the wrapped finished product at 40°C and keep it warm for 24 hours.

Embodiment 3

[0070] Tablet prescription: (made into 1000 tablets, each containing 75mg of venlafaxine hydrochloride)

[0071]

[0072] Coating solution: aqueous dispersion of ethyl acrylate-methyl methacrylate copolymer

[0073] Preparation process: pass the above raw materials and supplements through 80-mesh sieve respectively, then mix them evenly, make 16-mesh granules by wet method, dry them, add the prescribed amount of magnesium stearate, mix them evenly, press into tablets, then coat with the above coating solution, and Add talc. Place the wrapped finished product at 40°C and keep it warm for 24 hours.

technical field

[0001] The invention relates to the field of pharmaceutical preparations, in particular to a novel antidepressant venlafaxine hydrochloride sustained-release tablet preparation and a preparation method thereof. Background technique

[0002] Venlafaxine is a novel phenethylamine derivative. Its mechanism of action is different from that of tricyclic antidepressants and newer selective serotonin reuptake inhibitors in that it exerts antidepressant effects through inhibition of norepinephrine and serotonin reuptake and weak inhibition of dopamine reuptake. Depressive effect, no inhibitory effect on monoamine oxidase, no affinity with cholinergic, histaminergic, adrenergic and other receptors, so there are no adverse reactions related to these receptors, such as sedation, dry mouth, constipation, urinary retention and blurred vision . Venlafaxine is a new type of antidepressant with rapid onset, good tolerance, and good short-term and long-term therapeutic effe...

Examples

Embodiment 1

[0060] Tablet formula: (made into 1000 tablets, each containing venlafaxine hydrochloride 75mg)

[0061]

[0062] Coating solution: aqueous dispersion of ethyl acrylate-methyl methacrylate copolymer

[0063] Preparation process: pass the above raw materials and supplements through 80-mesh sieve respectively, then mix evenly, directly compress into tablets, then coat with the above coating solution, and add talcum powder. Place the wrapped finished product at 40°C and keep it warm for 24 hours.

Embodiment 2

[0065] Tablet prescription: (made into 1000 tablets, each containing 75mg of venlafaxine hydrochloride)

[0066]

[0067] Coating solution: aqueous dispersion of ethyl acrylate-methyl methacrylate copolymer

[0068] Preparation process: pass the above raw materials and supplements through 80-mesh sieve respectively, then mix them evenly, make 16-mesh granules by dry method, compress into tablets, then coat with the above-mentioned coating solution, and add appropriate amount of talcum powder. Place the wrapped finished product at 40°C and keep it warm for 24 hours.

Embodiment 3

[0070] Tablet prescription: (made into 1000 tablets, each containing 75mg of venlafaxine hydrochloride)

[0071]

[0072] Coating solution: aqueous dispersion of ethyl acrylate-methyl methacrylate copolymer

[0073] Preparation process: pass the above raw materials and supplements through 80-mesh sieve respectively, then mix them evenly, make 16-mesh granules by wet method, dry them, add the prescribed amount of magnesium stearate, mix them evenly, press into tablets, then coat with the above coating solution, and Add talc. Place the wrapped finished product at 40°C and keep it warm for 24 hours.

Images